Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 187

Showing 51-75 of 187 citing articles:

GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use
Konstantinos Arvanitakis, Theocharis Koufakis, Djordje S. Popovic, et al.
Current Obesity Reports (2023) Vol. 12, Iss. 2, pp. 61-74
Closed Access | Times Cited: 11
Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis
Xia Gu, Shimin Jiang, Yue Yang, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 4
The prevalence of cardiovascular diseases, chronic kidney disease, and obesity in patients with type 2 diabetes mellitus and the description of concurrent treatments: A two-center retrospective cross-sectional study in Saudi Arabia
Omar A. Alshaya, Ghazwa B. Korayem, Munirah Alghwainm, et al.
Saudi Pharmaceutical Journal (2024) Vol. 32, Iss. 5, pp. 102054-102054
Open Access | Times Cited: 4
Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: “INSIST” study
Kamel Mohammedi, Laurent Fauchier, Nadia Quignot, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
The Global Burden of Resistant Hypertension and Potential Treatment Options
Giacomo Buso, Claudia Agabiti Rosei, Matteo Lemoli, et al.
European Cardiology Review (2024) Vol. 19
Open Access | Times Cited: 4
No Differences in Kidney Function Decline Between People With Type 2 Diabetes Starting a Sodium-Glucose Cotransporter 2 Inhibitor or a Glucagon-like Peptide-1 Receptor Agonist: A Real-world Retrospective Comparative Observational Study
Sara Bodini, Silvia Pieralice, Luca D’Onofrio, et al.
Clinical Therapeutics (2024)
Open Access | Times Cited: 4
Cardiovascular risk associated with glucagon-like peptide-1 receptor agonists versus other conventional glucose-lowering drugs in patients with type-2 diabetes: protocol for a nationwide observational comparative study in routine care
Nicolas Danchin, Gilles Lemesle, Mikaël Mazighi, et al.
BMJ Open (2025) Vol. 15, Iss. 1, pp. e087790-e087790
Open Access
Konsensuspapier zum Management kardiovaskulärer Erkrankungen bei chronischer Nierenkrankheit
Katharina Marx-Schütt, Ulrich Kintscher, Johannes B. Dahm, et al.
Deleted Journal (2025)
Closed Access
Análise das diferentes respostas ao tratamento com agonistas GLP-1 em diabetes tipo 1 e tipo 2 e a personalização dos tratamentos
G. F. de Carvalho, GUSTAVO PACIFICO MAIA ANTERO DE SOUSA, Gabriel Moraes, et al.
Contribuciones a las Ciencias Sociales (2025) Vol. 18, Iss. 1, pp. e14682-e14682
Closed Access
Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices
B. Elad, Changhee Lee, Afsana Rahman, et al.
Artificial Organs (2025)
Closed Access
Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
Jincheng Shen, Amara Sarwal, Ravinder Singh, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Benefits of Glucagon-like Peptide-1 Receptor Agonists after Kidney Transplantation
Sukhdeep Sahi, Oscar A. Garcia Valencia, Jie Na, et al.
Endocrine Practice (2025)
Closed Access
Genetic Implications of Fatty Tissue for the Development of Ventricular Arrhythmias
Raluca Sirbu Prisecaru, Oana Purcar, Ioan Maniţiu
Cardiogenetics (2025) Vol. 15, Iss. 1, pp. 8-8
Open Access
Exendin-4 improves cerebral ischemia by relaxing microvessels, rapidly increasing cerebral blood flow after reperfusion
Yujie Chen, Lei Wang, Yutong Zhou, et al.
Basic Research in Cardiology (2025)
Closed Access
Body image and interest in GLP-1 weight loss medications
Charlotte N. Markey, Kristin J. August, D. S. Malik, et al.
Body Image (2025) Vol. 53, pp. 101890-101890
Open Access
Therapeutic potential of GLP-1RAs in sleep apnea with genetic associations to type 2 diabetes
Fang Cheng, Kang Yang, Yaoling Wang, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
Dimitra Vasdeki, Theocharis Koufakis, Georgios Tsamos, et al.
Nutrients (2022) Vol. 14, Iss. 22, pp. 4801-4801
Open Access | Times Cited: 18
Managing thrombotic risk in patients with diabetes
A. John Camm, Hani Sabbour, Oliver Schnell, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 17
Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
Kyu‐Sun Lee, Jung Hyun Noh, Seong‐Mi Park, et al.
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 1, pp. 10-26
Open Access | Times Cited: 10
Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure: a drug-target mendelian randomization and mediation analysis
Tianshi Mao, Jie Chen, Tong Su, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Chinese expert consensus on the management of hypertension in adults with type 2 diabetes
Xiaohui Pan, Hongbo He, Yuqian Bao, et al.
Journal of Evidence-Based Medicine (2024) Vol. 17, Iss. 4, pp. 851-864
Open Access | Times Cited: 3
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Baiju R. Shah, Harpreet S. Bajaj, Sonia Butalia, et al.
Canadian Journal of Diabetes (2024) Vol. 48, Iss. 7, pp. 415-424
Closed Access | Times Cited: 3
Association of GLP‐1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta‐Analysis
Ganesh Bushi, Mahalaqua Nazli Khatib, Shivam Rohilla, et al.
Diabetes/Metabolism Research and Reviews (2025) Vol. 41, Iss. 2
Open Access
Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation
Merita Rroji, Nereida Spahia, Andreja Figurek, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 728-728
Open Access
The Efficacy and Safety of GLP-1 RAs in the Modification of Cardiovascular Morbidity in Patients with Obesity Without Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials Involving 32,884 Patients
Mohammad Tanashat, Yazan A. Al‐Ajlouni, Mohamed Gaber, et al.
American Journal of Cardiovascular Drugs (2025)
Closed Access

Scroll to top